Skip to main content
JAMA Network logoLink to JAMA Network
. 2020 Oct 29;3(10):e2027727. doi: 10.1001/jamanetworkopen.2020.27727

Omission in Funding/Support

PMCID: PMC7596580  PMID: 33119101

In the Original Investigation titled “Trends in the Use of Stereotactic Body Radiotherapy for Treatment of Prostate Cancer in the United States,”1 published February 5, 2020, there was an omission in the Funding/Support section in the Article Information. Dr Hu’s research was supported by The Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust. This article has been corrected.1

Reference

  • 1.Mahase SS, D’Angelo D, Kang J, Hu JC, Barbieri CE, Nagar H. Trends in the use of stereotactic body radiotherapy for treatment of prostate cancer in the United States. JAMA Netw Open. 2020;3(2):e1920471. doi: 10.1001/jamanetworkopen.2019.20471 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from JAMA Network Open are provided here courtesy of American Medical Association

RESOURCES